China's Nanjing Leads Biolabs more than doubles in Hong Kong debut

Nanjing Leads Biolabs

25/07/2025 07:27

** Shares of Chinese biotechnology group Nanjing Leads Biolabs 9887.HK trade as high as at HK$79.6 each in Hong Kong debut, up 127.4% from their offer price

** Stock last up 104.6% compared to HK$35 apiece offer price, with 30.9 mln shares worth HK$2.2 bln changing hands in early afternoon trade

** Stock tracks Hang Seng Biotech Index .HSHKBIO, which is up as much as 1.6% to 16,121.25 points, highest level since January 2022

** The company offered 32.05 mln shares in IPO, raising HK$1.12 bln ($142.69 mln)

** It priced shares at top end of the offer range of HK$31.60 to HK$35 apiece; retail tranche of the public offering was 3,494.8 times subscribed

** Hong Kong's healthcare index .HSCIH climbs as much as 1.5% to 13,181.63 points, highest level since February 2023

** Both the Hang Seng Biotech Index and the healthcare index slip 0.3% in afternoon trade

($1 = 7.8492 Hong Kong dollars)

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))